STERIS plc reported a 10% increase in total revenue for Q4 2024, reaching $1.5 billion, driven by strong performance in the Healthcare segment. However, the company experienced a U.S. GAAP net loss of $1.4 million, or ($0.01) per diluted share, due to a pre-tax loss from the reclassification of the Dental segment as discontinued operations and charges related to a targeted restructuring program. Adjusted net income for the quarter was $256.3 million, or $2.58 per diluted share.
Total revenue increased by 10% to $1.5 billion compared to Q4 2023.
U.S. GAAP net loss was $1.4 million, or ($0.01) per diluted share, impacted by discontinued operations and restructuring.
Adjusted net income was $256.3 million, or $2.58 per diluted share, compared to $229.2 million, or $2.30 per diluted share in the previous year’s fourth quarter.
Healthcare segment revenue grew by 14%, driven by capital equipment, consumable, and service revenue growth.
For fiscal year 2025, STERIS expects as reported revenue from continuing operations to increase 6.5-7.5%. Adjusted earnings per diluted share from continuing operations are anticipated to be in the range of $9.05 to $9.25.
Visualization of income flow from segment revenue to net income